trial

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

NCTId NCT00129441
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 16 (actual)
Sponsored by University of Pittsburgh Medical Center
Primary completion 2008-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2005-08
Primary completion
2008-01
Eligibility
MALE · 18 Years · 50 Years

Interventions & indications

Drugs
Merck L-830982

Sponsors

University of Pittsburgh Medical CenterLead Sponsor
Merck Sharp & Dohme LLCCollaborator

Investigators

1
David A Lewis, MDPrincipal Investigator

Sites

1 total
Pittsburgh, United States

Linked catalysts

1
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study — primary completion2008-01

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE2
Primary Completion Date
2008-01
Status
COMPLETED
relationships
The graph out of here
drug
Merck L-830982
drug
lead_sponsor
University of Pittsburgh Medical Center
company
collaborator
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David A Lewis, MD
person